


# Quantitative Systems Pharmacology (QSP) Diffuse Large B Cell Lymphoma (DLBCL) Model





- · Predict efficacy for late-stage therapeutics under development, including CAR-T therapy and combination therapies
- · Compare different therapeutics with the same or similar targets or against existing treatments
- Determine patient subgroups of interest based on baseline patient features or response to specific lines of therapy
- Find saturating doses of novel immunologic therapeutics

# **Key Features**

- Convenient, efficient, and thorough generation and calibration of virtual populations
- Includes both qualitative and quantitative data during model training
- Represents clinical trials with specific entrance
- Plot and analyze simulation results in the same platform
- Automatically visualize connections between model components
- Export data to other programs for ad hoc analyses

## **Sound Science**



### Clinical data

constrains the relative contribution of distinct pathways to tumor growth and suppression via inclusion of numerous therapeutic classes (eg, immunomodulatory drugs, combination chemotherapy such as R-CHOP, etc.)



#### Generates

virtual populations that include inter-patient variability in pathophysiology as well as clinical endpoints



#### Includes

detailed interactions between the tumor in the bone marrow and immune response



#### Considers

tumor geometry in order to accommodate endpoints depending on tumor size and shape



#### **Incorporates**

cellular and biochemical processes across multiple scales, from cytokine concentrations to clinical responses



oncological processes are explicitly represented, including IL2-based expansion of both endogenous and CAR-T cells



Connect with us: 🖪 💟 in 🗖







